These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 17716229)
21. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. Maloney B; Ge YW; Alley GM; Lahiri DK J Neurochem; 2007 Nov; 103(3):1237-57. PubMed ID: 17854398 [TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. Li FQ; Sempowski GD; McKenna SE; Laskowitz DT; Colton CA; Vitek MP J Pharmacol Exp Ther; 2006 Sep; 318(3):956-65. PubMed ID: 16740622 [TBL] [Abstract][Full Text] [Related]
23. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Lynch JR; Wang H; Mace B; Leinenweber S; Warner DS; Bennett ER; Vitek MP; McKenna S; Laskowitz DT Exp Neurol; 2005 Mar; 192(1):109-16. PubMed ID: 15698624 [TBL] [Abstract][Full Text] [Related]
24. [Progress of the recovery mechanism of brain injury associated with the gene polymorphism of apolipoproteins E]. You Y; Li RB Fa Yi Xue Za Zhi; 2014 Dec; 30(6):466-9. PubMed ID: 25816582 [TBL] [Abstract][Full Text] [Related]
25. [Clinical and prognostic significance of genetic markers of ApoE gene in traumatic brain injury]. Potapov AA; Iusupova MM; Tendieva VD; Nikitin AG; Nosikov VV Zh Vopr Neirokhir Im N N Burdenko; 2010; (3):54-62; discussion 62. PubMed ID: 21254576 [TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein E polymorphisms status in Iranian patients with multiple sclerosis. Rafiei M; Zarif Yeganeh M; Sheikholeslami S; Gozalpour E; Ghaffarpour M; Hedayati M J Neurol Sci; 2012 Sep; 320(1-2):22-5. PubMed ID: 22698480 [TBL] [Abstract][Full Text] [Related]
27. The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis. Fazekas F; Enzinger C; Ropele S; Schmidt H; Schmidt R; Strasser-Fuchs S J Neurol Sci; 2006 Jun; 245(1-2):35-9. PubMed ID: 16631796 [TBL] [Abstract][Full Text] [Related]
28. Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease. Bales KR Neuropharmacology; 2010; 59(4-5):295-302. PubMed ID: 20079752 [TBL] [Abstract][Full Text] [Related]
30. Recent advances in the pharmacology of neurological gene therapy. Lowenstein PR; Castro MG Curr Opin Pharmacol; 2004 Feb; 4(1):91-7. PubMed ID: 15018845 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury. James ML; Komisarow JM; Wang H; Laskowitz DT Neurotherapeutics; 2020 Apr; 17(2):475-483. PubMed ID: 32318912 [TBL] [Abstract][Full Text] [Related]
32. From genes to mechanisms to therapies: lessons to be learned from neurological disorders. Roses AD Nat Med; 1996 Mar; 2(3):267-9. PubMed ID: 8612215 [No Abstract] [Full Text] [Related]
33. Neurogenetics in the postgenomic era. Tsuji S Arch Neurol; 2001 Nov; 58(11):1758-9. PubMed ID: 11708980 [No Abstract] [Full Text] [Related]
34. New order from neurological disorders. Price DL Nature; 1999 Jun; 399(6738 Suppl):A3-5. PubMed ID: 10392574 [TBL] [Abstract][Full Text] [Related]
35. Targeting glia for treatment of neurological disease. Rempe DA; Nedergaard M Neurotherapeutics; 2010 Oct; 7(4):335-7. PubMed ID: 20880498 [No Abstract] [Full Text] [Related]
36. Editorial (Thematic Issue: Molecular and Cellular Engineering Approaches for Neurological Disorders, Diseases, and Injuries Involved the Central and Peripheral Nervous Systems). Suh YH; Suh WH CNS Neurol Disord Drug Targets; 2016; 15(8):878-880. PubMed ID: 27875959 [No Abstract] [Full Text] [Related]